ZJY-54

ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC50 values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity[1].

Product Specifications

UNSPSC

12352211

Target

EGFR; Histone Demethylase

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

COC1=C(C=C(C(N2C[C@@H](CC2)N(C)C)=C1)NC(C=C)=O)NC3=NC(C4=CN(C([2H])([2H])[2H])C5=CC=CC=C54)=CC=N3

Molecular Formula

C29H30D3N7O2

Molecular Weight

514.64

References & Citations

[1]Zhang J, et al. Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers. J Med Chem. 2025 Mar 13;68 (5) :5954-5972.